Catharine M L West

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2796669/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652
2	Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nature Reviews Cancer, 2009, 9, 134-142.	28.4	593
3	Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. British Journal of Cancer, 2010, 102, 428-435.	6.4	440
4	Relation of a Hypoxia Metagene Derived from Head and Neck Cancer to Prognosis of Multiple Cancers. Cancer Research, 2007, 67, 3441-3449.	0.9	349
5	Imaging tumour hypoxia with positron emission tomography. British Journal of Cancer, 2015, 112, 238-250.	6.4	272
6	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264
7	The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. British Journal of Cancer, 2011, 104, 1168-1177.	6.4	244
8	Head and neck cancer-Part 1: Epidemiology, presentation, and prevention. BMJ: British Medical Journal, 2010, 341, c4684-c4684.	2.3	216
9	hsaâ€miRâ€210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer, 2010, 116, 2148-2158.	4.1	215
10	A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer. Clinical Cancer Research, 2013, 19, 4879-4888.	7.0	214
11	GLUTâ€∎ and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding. International Journal of Cancer, 2003, 104, 85-91.	5.1	205
12	Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncology, The, 2012, 13, 65-77.	10.7	202
13	Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiotherapy and Oncology, 2000, 57, 53-59.	0.6	197
14	Targeting Hypoxia to Improve Non–Small Cell Lung Cancer Outcome. Journal of the National Cancer Institute, 2018, 110, 14-30.	6.3	177
15	Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. International Journal of Radiation Oncology Biology Physics, 2002, 54, 759-767.	0.8	165
16	Genetics and genomics of radiotherapy toxicity: towards prediction. Genome Medicine, 2011, 3, 52.	8.2	144
17	Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiotherapy and Oncology, 1995, 37, 1-9.	0.6	143
18	Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiotherapy and Oncology, 2003, 67, 35-44.	0.6	140

#	Article	IF	CITATIONS
19	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. EBioMedicine, 2018, 31, 182-189.	6.1	132
20	A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiotherapy and Oncology, 2014, 111, 178-185.	0.6	128
21	HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology. Cancer Research, 2016, 76, 6598-6606.	0.9	128
22	Hypoxia-Inducible Factor 1α Expression as an Intrinsic Marker of Hypoxia. Clinical Cancer Research, 2004, 10, 8405-8412.	7.0	123
23	Establishment of a Radiogenomics Consortium. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1295-1296.	0.8	118
24	lonizing radiation biomarkers in epidemiological studies – An update. Mutation Research - Reviews in Mutation Research, 2017, 771, 59-84.	5.5	118
25	Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. British Journal of Cancer, 2012, 107, 684-694.	6.4	116
26	Combretastatin A4 phosphate. Anti-Cancer Drugs, 2004, 15, 179-187.	1.4	115
27	A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. Nature Genetics, 2014, 46, 891-894.	21.4	114
28	Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. International Journal of Radiation Oncology Biology Physics, 2000, 46, 13-19.	0.8	113
29	Preliminary Study of Oxygen-Enhanced Longitudinal Relaxation in MRI: A Potential Novel Biomarker of Oxygenation Changes in Solid Tumors. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1209-1215.	0.8	107
30	A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients. Clinical Cancer Research, 2017, 23, 4761-4768.	7.0	107
31	Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?. British Journal of Cancer, 2003, 89, 870-876.	6.4	100
32	Chromosomal radiosensitivity as a marker of predisposition to common cancers?. British Journal of Cancer, 2001, 84, 892-896.	6.4	99
33	Radiogenomics: Radiobiology Enters the Era of Big Data and Team Science. International Journal of Radiation Oncology Biology Physics, 2014, 89, 709-713.	0.8	99
34	The biology of photodynamic therapy. Physics in Medicine and Biology, 1997, 42, 913-935.	3.0	98
35	The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: A prospective international multi-center study. Radiotherapy and Oncology, 2006, 80, 123-131.	0.6	98
36	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. Radiotherapy and Oncology, 2016, 121, 431-439.	0.6	98

#	Article	IF	CITATIONS
37	A Comparison of the Radiosensitivity of Lymphocytes from Normal Donors, Cancer Patients, Individuals with Ataxia-telangiectasia (A-T) and A-T Heterozygotes. International Journal of Radiation Biology, 1995, 68, 197-203.	1.8	96
38	Hypoxia-inducible factor-1α expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. British Journal of Cancer, 2007, 96, 95-103.	6.4	94
39	Expression of Ku70 correlates with survival in carcinoma of the cervix. British Journal of Cancer, 2000, 83, 1702-1706.	6.4	92
40	A comparison of tracer kinetic models for <i>T</i> ₁ -weighted dynamic contrast-enhanced MRI: Application in carcinoma of the cervix. Magnetic Resonance in Medicine, 2010, 63, 691-700.	3.0	92
41	Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncology, The, 2015, 16, 1515-1524.	10.7	90
42	Lysyl Oxidase: From Basic Science to Future Cancer Treatment. Cell Structure and Function, 2012, 37, 75-80.	1.1	89
43	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	12.8	88
44	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
45	Epigenetic downregulation of human disabled homolog 2 switches TGF-β from a tumor suppressor to a tumor promoter. Journal of Clinical Investigation, 2010, 120, 2842-2857.	8.2	87
46	Expression of hypoxia-inducible factor 1α in thyroid carcinomas. Endocrine-Related Cancer, 2010, 17, 61-72.	3.1	84
47	Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer. Clinical Cancer Research, 2019, 25, 5315-5328.	7.0	81
48	Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. International Journal of Radiation Oncology Biology Physics, 2001, 49, 581-586.	0.8	79
49	Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. International Journal of Radiation Oncology Biology Physics, 2007, 67, 84-90.	0.8	77
50	Hypoxia in head and neck cancer. British Journal of Radiology, 2006, 79, 791-798.	2.2	76
51	Dynamic contrast-enhanced magnetic resonance imaging biomarkers in head and neck cancer: Potential to guide treatment? A systematic review. Oral Oncology, 2014, 50, 963-970.	1.5	74
52	The REQUITE Project: Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-effects and Improve Quality of Life in Cancer Survivors. Clinical Oncology, 2014, 26, 739-742.	1.4	73
53	Lymphocyte radiosensitivity is a significant prognostic factor for morbidity in carcinoma of the cervix. International Journal of Radiation Oncology Biology Physics, 2001, 51, 10-15.	0.8	72
54	Spectral Clustering of Microarray Data Elucidates the Roles of Microenvironment Remodeling and Immune Responses in Survival of Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology, 2010, 28, 2881-2888.	1.6	72

#	Article	IF	CITATIONS
55	Head and neck cancerPart 2: Treatment and prognostic factors. BMJ: British Medical Journal, 2010, 341, c4690-c4690.	2.3	72
56	Radiosensitivity testing of primary cervical carcinoma: evaluation of intra- and inter-tumour heterogeneity. Radiotherapy and Oncology, 1990, 18, 349-356.	0.6	71
57	Is the hypoxia-inducible factor pathway important in gastric cancer?. European Journal of Cancer, 2005, 41, 2792-2805.	2.8	71
58	Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. Journal of the National Cancer Institute, 2020, 112, 179-190.	6.3	71
59	Evaluation of Surviving Fraction at 2 Gy as a Potential Prognostic Factor for the Radiotherapy of Carcinoma of the Cervix. International Journal of Radiation Biology, 1989, 56, 761-765.	1.8	70
60	NIMRAD – A Phase III Trial to Investigate the Use of Nimorazole Hypoxia Modification with Intensity-modulated Radiotherapy in Head and Neck Cancer. Clinical Oncology, 2014, 26, 344-347.	1.4	70
61	Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. Oncotarget, 2017, 8, 14416-14427.	1.8	70
62	Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. EBioMedicine, 2016, 10, 150-163.	6.1	69
63	The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2019, 105, 698-712.	0.8	69
64	Tumour budding and a low host inflammatory response are associated with a poor prognosis in oesophageal and gastroâ€oesophageal junction cancers. Histopathology, 2010, 56, 893-899.	2.9	68
65	Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?. Cancer Letters, 2016, 382, 95-109.	7.2	68
66	A replicated association between polymorphisms near TNFα and risk for adverse reactions to radiotherapy. British Journal of Cancer, 2012, 107, 748-753.	6.4	66
67	Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. Radiotherapy and Oncology, 2012, 105, 289-295.	0.6	65
68	XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1084-1092.	0.8	64
69	Perfusion Estimated With Rapid Dynamic Contrast-Enhanced Magnetic Resonance Imaging Correlates Inversely With Vascular Endothelial Growth Factor Expression and Pimonidazole Staining in Head-and-Neck Cancer: A Pilot Study. International Journal of Radiation Oncology Biology Physics, 2011 81, 1176 1182	0.8	63
70	Standardized Total Average Toxicity Score: A Scale- and Grade-Independent Measure of Late Radiotherapy Toxicity to Facilitate Pooling of Data From Different Studies. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1065-1074.	0.8	63
71	Radiogenomics: the search for genetic predictors of radiotherapy response. Future Oncology, 2014, 10, 2391-2406.	2.4	63
72	Development and validation of a nomogram for prediction of survival and local control in laryngeal carcinoma patients treated with radiotherapy alone: A cohort study based on 994 patients. Radiotherapy and Oncology, 2011, 100, 108-115.	0.6	62

#	Article	IF	CITATIONS
73	STROGAR – STrengthening the Reporting Of Genetic Association studies in Radiogenomics. Radiotherapy and Oncology, 2014, 110, 182-188.	0.6	59
74	The intrinsic radiosensitivity of cervical carcinoma: correlations with clinical data. International Journal of Radiation Oncology Biology Physics, 1995, 31, 841-846.	0.8	57
75	Evaluation of the LENT-SOMA scales for the prospective assessment of treatment morbidity in cervical carcinoma. International Journal of Radiation Oncology Biology Physics, 2003, 56, 502-510.	0.8	56
76	Establishment of a radiogenomics consortium. Radiotherapy and Oncology, 2010, 94, 117-118.	0.6	56
77	Head and neck cancer—Part 1: Epidemiology, presentation, and preservation. Clinical Otolaryngology, 2011, 36, 65-68.	1.2	56
78	A correlation between residual radiation-induced DNA double-strand breaks in cultured fibroblasts and late radiotherapy reactions in breast cancer patients. Radiotherapy and Oncology, 1999, 51, 55-65.	0.6	55
79	Prediction of cervical carcinoma response to radiotherapy. Lancet, The, 1991, 338, 818.	13.7	54
80	Incorporating biologic measurements (SF2, CFE) into a tumor control probability model increases their prognostic significance: a study in cervical carcinoma treated with radiation therapy. International Journal of Radiation Oncology Biology Physics, 2001, 50, 1113-1122.	0.8	54
81	The Genomics Revolution and Radiotherapy. Clinical Oncology, 2007, 19, 470-480.	1.4	54
82	No association between SNPs regulating TGF-β1 secretion and late radiotherapy toxicity to the breast: Results from the RAPPER study. Radiotherapy and Oncology, 2010, 97, 9-14.	0.6	54
83	Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. Radiotherapy and Oncology, 2013, 108, 40-47.	0.6	54
84	A Comparison of the Sensitivity to Photodynamic Treatment of Endothelial and Tumour Cells in Different Proliferative States. International Journal of Radiation Biology, 1990, 58, 145-156.	1.8	53
85	Imaging vascular physiology to monitor cancer treatment. Critical Reviews in Oncology/Hematology, 2006, 58, 95-113.	4.4	53
86	Statistical Considerations of Optimal Study Design for Human Plasma Proteomics and Biomarker Discovery. Journal of Proteome Research, 2012, 11, 2103-2113.	3.7	53
87	The Prognostic Significance of the Biomarker p16 in Oropharyngeal Squamous Cell Carcinoma. Clinical Oncology, 2013, 25, 630-638.	1.4	53
88	REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiotherapy and Oncology, 2019, 138, 59-67.	0.6	53
89	Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. Clinical Otolaryngology, 2007, 32, 337-345.	1.2	52
90	Enhancing fraction measured using dynamic contrast-enhanced MRI predicts disease-free survival in patients with carcinoma of the cervix. British Journal of Cancer, 2010, 102, 23-26.	6.4	52

#	Article	IF	CITATIONS
91	Changes in oxygenation during radiotherapy in carcinoma of the cervix. International Journal of Radiation Oncology Biology Physics, 1999, 45, 119-126.	0.8	51
92	FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 145-156.	2.8	51
93	Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. International Journal of Radiation Oncology Biology Physics, 2018, 101 274-284	0.8	50
94	The intrinsic radiosensitivity of normal and tumour cells. International Journal of Radiation Biology, 1998, 73, 409-413.	1.8	49
95	Prognostic Significance of Tumor Hypoxia Inducible Factor–1α Expression for Outcome After Radiotherapy in Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1551-1559.	0.8	49
96	Apoptosis as predictor of response to radiotherapy in cervical carcinoma. Lancet, The, 1994, 344, 472.	13.7	47
97	Chromosomal radiosensitivity in young cancer patients: possible evidence of genetic predisposition. International Journal of Radiation Biology, 2002, 78, 341-346.	1.8	46
98	Radiosensitivity, Radiogenomics and RAPPER. Clinical Oncology, 2006, 18, 525-528.	1.4	46
99	Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia–dysplasia–adenocarcinoma sequence. British Journal of Cancer, 2007, 96, 1377-1383.	6.4	46
100	Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 66, 331-338.	0.8	44
101	Radiogenomics and radiotherapy response modeling. Physics in Medicine and Biology, 2017, 62, R179-R206.	3.0	43
102	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 2018, 9, 4616.	12.8	43
103	Investigation of Radiosensitivity Gene Signatures in Cancer Cell Lines. PLoS ONE, 2014, 9, e86329.	2.5	43
104	Tumour vascularity is a significant prognostic factor for cervix carcinoma treated with radiotherapy: Independence from tumour radiosensitivity. British Journal of Cancer, 1999, 81, 354-358.	6.4	42
105	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nature Communications, 2021, 12, 1236.	12.8	40
106	The radiosensitivity of human fibroblast cell lines correlates with residual levels of DNA double-strand breaks. Radiotherapy and Oncology, 1998, 47, 271-276.	0.6	39
107	FTIR microspectroscopy of selected rare diverse subâ€variants of carcinoma of the urinary bladder. Journal of Biophotonics, 2013, 6, 73-87.	2.3	38
108	Expression of hypoxia-inducible factor- $1\hat{l}$ ± predicts benefit from hypoxia modification in invasive bladder cancer. British Journal of Cancer, 2014, 111, 437-443.	6.4	38

#	Article	IF	CITATIONS
109	Use of Low-dose Rate Irradiation to Measure the Intrinsic Radiosensitivity of Human T-lymphocytes. International Journal of Radiation Biology, 1993, 64, 375-383.	1.8	37
110	The immunohistochemical expression of DNA-PKcs and Ku (p70/p80) in head and neck cancers: relationships with radiosensitivity. International Journal of Radiation Oncology Biology Physics, 1999, 45, 1005-1010.	0.8	37
111	Radiation response and cure rate of human colon adenocarcinoma spheroids of different size: the significance of hypoxia on tumor control modelling. International Journal of Radiation Oncology Biology Physics, 2001, 49, 1109-1118.	0.8	37
112	Exon Array Analysis of Head and Neck Cancers Identifies a Hypoxia Related Splice Variant of LAMA3 Associated with a Poor Prognosis. PLoS Computational Biology, 2009, 5, e1000571.	3.2	37
113	Incorporating Genetic Biomarkers into Predictive Models of Normal Tissue Toxicity. Clinical Oncology, 2015, 27, 579-587.	1.4	37
114	Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters. Scientific Reports, 2018, 8, 16804.	3.3	37
115	A correlation between residual DNA double-strand breaks and clonogenic measurements of radiosensitivity in fibroblasts from preradiotherapy cervix cancer patients. International Journal of Radiation Oncology Biology Physics, 1997, 39, 1137-1144.	0.8	36
116	Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma. European Journal of Cancer, 2013, 49, 156-165.	2.8	36
117	Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. Frontiers in Oncology, 2017, 7, 83.	2.8	36
118	The Radiation Response of a Human Colon Adenocarcinoma Grown in Monolayer, as Spheroids, and in Nude Mice. Radiation Research, 1987, 112, 105.	1.5	35
119	Assessment of morbidity in carcinoma of the cervix: a comparison of the LENT SOMA scales and the Franco-Italian glossary. Radiotherapy and Oncology, 2003, 69, 195-200.	0.6	35
120	The potential of positron-emission tomography to study anticancer-drug resistance. Nature Reviews Cancer, 2004, 4, 457-469.	28.4	35
121	Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts. Oncotarget, 2018, 9, 3946-3955.	1.8	35
122	Spatial proximity between T and PD-L1 expressing cells as a prognostic biomarker for oropharyngeal squamous cell carcinoma. British Journal of Cancer, 2020, 122, 539-544.	6.4	35
123	Differential Expression of Cytokine Genes in Fibroblasts Derived from Skin Biopsies of Patients who Developed Minimal or Severe Normal Tissue Damage after Radiotherapy. Radiation Research, 2002, 157, 243-248.	1.5	34
124	The FOXM1-PLK1 axis is commonly upregulated in oesophageal adenocarcinoma. British Journal of Cancer, 2012, 107, 1766-1775.	6.4	34
125	Molecular and cellular processes underlying the hallmarks of head and neck cancer. European Archives of Oto-Rhino-Laryngology, 2013, 270, 2585-2593.	1.6	33
126	Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399). International Journal of Radiation Oncology Biology Physics, 2021, 110, 1407-1415.	0.8	33

#	Article	IF	CITATIONS
127	Hypoxia-associated markers in gastric carcinogenesis and HIF-2α in gastric and gastro-oesophageal cancer prognosis. British Journal of Cancer, 2008, 98, 965-973.	6.4	31
128	A high ratio of apoptosis to proliferation correlates with improved survival after radiotherapy for cervical adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 1999, 44, 507-512.	0.8	30
129	Genetic Variants Predict Optimal Timing of Radiotherapy to Reduce Side-effects in Breast Cancer Patients. Clinical Oncology, 2019, 31, 9-16.	1.4	30
130	Cell Survival Characteristics of a Human Colon Adenocarcinoma Cell Line after Photodynamic Treatment: A Comparison of Photofrin II and TPPS. International Journal of Radiation Biology, 1988, 54, 621-634.	1.8	29
131	Exon-array profiling unlocks clinically and biologically relevant gene signatures from formalin-fixed paraffin-embedded tumour samples. British Journal of Cancer, 2011, 104, 971-981.	6.4	29
132	A radiobiological comparison of human tumor soft-agar clonogenic assays. International Journal of Cancer, 1986, 37, 897-903.	5.1	28
133	RAPPER: The Radiogenomics of Radiation Toxicity. Clinical Oncology, 2013, 25, 431-434.	1.4	28
134	Use of an Internal Standard in Comparative Measurements of the Intrinsic Radiosensitivities of Human T-lymphocytes. International Journal of Radiation Biology, 1993, 64, 385-391.	1.8	27
135	Tumour stem cells: the relevance of predictive assays for tumour control after radiotherapy. Radiotherapy and Oncology, 1994, 30, 11-16.	0.6	27
136	Epidermal growth factor receptor-targeted therapy. British Journal of Radiology, 2008, 81, S36-S44.	2.2	27
137	Pretreatment plasma TGFβ1 levels are prognostic for survival but not morbidity following radiation therapy of carcinoma of the cervix. International Journal of Radiation Oncology Biology Physics, 2000, 48, 991-995.	0.8	26
138	Development of a patient-reported questionnaire for collecting toxicity data following prostate brachytherapy. Radiotherapy and Oncology, 2010, 97, 136-142.	0.6	26
139	Mitochondrial DNA mutations in head and neck cancer are infrequent and lack prognostic utility. British Journal of Cancer, 2011, 104, 1319-1324.	6.4	26
140	Relationships between clonogenic cell survival, DNA damage and chromosomal radiosensitivity in nine human cervix carcinoma cell lines. International Journal of Radiation Biology, 2001, 77, 295-302.	1.8	25
141	The prognostic value of dynamic contrast-enhanced MRI contrast agent transfer constant Ktrans in cervical cancer is explained by plasma flow rather than vessel permeability. British Journal of Cancer, 2017, 116, 1436-1443.	6.4	25
142	Radiation biology and oncology in the genomic era. British Journal of Radiology, 2018, 91, 20170949.	2.2	25
143	Independence of HIF1a and androgen signaling pathways in prostate cancer. BMC Cancer, 2020, 20, 469.	2.6	25
144	Osteoradionecrosis in Head-and-Neck Cancer Has a Distinct Genotype-Dependent Cause. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1479-1484.	0.8	24

#	Article	IF	CITATIONS
145	Loss of expression of the tumour suppressor gene <i>AIMP3</i> predicts survival following radiotherapy in muscleâ€invasive bladder cancer. International Journal of Cancer, 2015, 136, 709-720.	5.1	24
146	Short Report: A Morbidity Scoring System for Clinical Oncology Practice: Questionnaires produced from the LENT SOMA scoring system. Clinical Oncology, 2002, 14, 68-69.	1.4	23
147	Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer: Controversies and Future developments. Clinical Oncology, 2005, 17, 591-598.	1.4	23
148	Measurement tools for gastrointestinal symptoms in radiation oncology. Current Opinion in Supportive and Palliative Care, 2009, 3, 36-40.	1.3	23
149	Genome-Wide Association Studies and Prediction of Normal Tissue Toxicity. Seminars in Radiation Oncology, 2012, 22, 91-99.	2.2	23
150	MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 104, 809-818.	0.8	23
151	Guidelines for using sigQC for systematic evaluation of gene signatures. Nature Protocols, 2019, 14, 1377-1400.	12.0	23
152	The lack of correlation between proliferation (Ki-67, PCNA, LI, Tpot), p53 expression and radiosensitivity for head and neck cancers. British Journal of Cancer, 1999, 80, 1400-1404.	6.4	22
153	Prognostic significance of c -erb  B-2 protein expression in carcinoma of the cervix treated with radiotherapy. Journal of Cancer Research and Clinical Oncology, 1999, 125, 96-100.	2.5	22
154	Relationship between residual radiation-induced DNA double-strand breaks in cultured fibroblasts and late radiation reactions: a comparison of training and validation cohorts of breast cancer patients. Radiotherapy and Oncology, 2002, 62, 321-326.	0.6	22
155	Thoracic Radiation Therapy for Limited-Stage Small-Cell Lung Cancer: Unanswered Questions. Clinical Lung Cancer, 2005, 7, 23-29.	2.6	22
156	Blood flow and Vd (water): both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue. Molecular Cancer Therapeutics, 2009, 8, 303-309.	4.1	22
157	Prognostic value of hypoxiaâ€associated markers in advanced larynx and hypopharynx squamous cell carcinoma. Laryngoscope, 2015, 125, E8-15.	2.0	22
158	THE PHOTODYNAMIC EFFECTS OF PHOTOFRIN II, HEMATOPORPHYRIN DERIVATIVE, HEMATOPORPHYRIN, AND TETRASODIUM-MESO-TETRA(4-SULFONATOPHENYL)PORPHINE in vitro: Photochemistry and Photobiology, 1989, 49, 169-174.	2.5	21
159	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 208-216.	2.5	21
160	Lost in application: Measuring hypoxia for radiotherapy optimisation. European Journal of Cancer, 2021, 148, 260-276.	2.8	21
161	MECHANISMS BEHIND THE RESISTANCE OF SPHEROIDS TO PHOTODYNAMIC TREATMENT: A FLOW CYTOMETRY STUDY. Photochemistry and Photobiology, 1992, 55, 425-430.	2.5	20
162	Will SNPs be useful predictors of normal tissue radiosensitivity in the future?. Radiotherapy and Oncology, 2012, 105, 283-288.	0.6	20

#	Article	lF	CITATIONS
163	Lack of Prognostic Effect of Carbonic Anhydrase-9, Hypoxia Inducible Factor-1α and Bcl-2 in 286 Patients with Early Squamous Cell Carcinoma of the Glottic Larynx Treated with Radiotherapy. Clinical Oncology, 2013, 25, 59-65.	1.4	20
164	Tumor plasma flow determined by dynamic contrast-enhanced MRI predicts response to induction chemotherapy in head and neck cancer. Oral Oncology, 2015, 51, 508-513.	1.5	20
165	The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma. British Journal of Cancer, 2018, 118, 698-704.	6.4	20
166	Radiogenomics in the Era of Advanced Radiotherapy. Clinical Oncology, 2019, 31, 319-325.	1.4	20
167	Computed tomography overestimation of esophageal tumor length: Implications for radiotherapy planning. World Journal of Gastrointestinal Oncology, 2010, 2, 197.	2.0	20
168	Ability to undergo apoptosis does not correlate with the intrinsic radiosensitivity (SF2) of human cervix tumor cell lines. International Journal of Radiation Oncology Biology Physics, 2001, 50, 503-509.	0.8	19
169	Expression of the proapoptotic protein Bid is an adverse prognostic factor for radiotherapy outcome in carcinoma of the cervix. British Journal of Cancer, 2005, 92, 449-458.	6.4	18
170	The degree of circumferential tumour involvement as a prognostic factor in oesophageal cancerâ~†â~†â~†. European Journal of Cardio-thoracic Surgery, 2009, 36, 368-373.	1.4	17
171	Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity. British Journal of Cancer, 2016, 114, 1165-1174.	6.4	17
172	Impact of hypoxia on cervical cancer outcomes. International Journal of Gynecological Cancer, 2021, 31, 1459-1470.	2.5	17
173	Growth phase related variation in the radiation sensitivity of human colon adenocarcinoma cells. International Journal of Radiation Oncology Biology Physics, 1988, 14, 1213-1219.	0.8	16
174	The lower radiosensitivity of mouse kidney cells irradiated in vivo than in vitro: A cell contact effect phenomenon. International Journal of Radiation Oncology Biology Physics, 1991, 20, 1243-1248.	0.8	16
175	Lack of correlation between residual radiation-induced DNA damage, in keratinocytes assayed directly from skin, and late radiotherapy reactions in breast cancer patients. International Journal of Radiation Oncology Biology Physics, 1999, 43, 481-487.	0.8	16
176	Tumor Epression of Major Vault Protein is an Adverse Prognostic Factor for Radiotherapy Outcome in Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 133-140.	0.8	16
177	Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. Translational Oncology, 2014, 7, 55-64.	3.7	16
178	Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity. Clinical Cancer Research, 2016, 22, 1413-1420.	7.0	16
179	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers, 2020, 12, 3254.	3.7	16
180	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 532-541.	3.9	16

#	Article	IF	CITATIONS
181	FLOW CYTOMETRIC ANALYSIS OF INTRACELLULAR HEMATOPORPHYRIN DERIVATIVE IN HUMAN TUMOR CELLS AND MULTICELLULAR SPHEROIDS. Photochemistry and Photobiology, 1989, 50, 665-669.	2.5	15
182	An in vivo hypoxia metagene identifies the novel hypoxia inducible factor target gene SLCO1B3. European Journal of Cancer, 2013, 49, 1741-1751.	2.8	15
183	Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement. Radiotherapy and Oncology, 2016, 121, 440-446.	0.6	15
184	Tumour Hypoxia. Clinical Oncology, 2019, 31, 595-599.	1.4	15
185	Use of a novel atlas for muscles of mastication to reduce inter observer variability in head and neck radiotherapy contouring. Radiotherapy and Oncology, 2019, 130, 56-61.	0.6	15
186	A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. Frontiers in Oncology, 2020, 10, 541281.	2.8	15
187	An evaluation of MR based deep learning auto-contouring for planning head and neck radiotherapy. Radiotherapy and Oncology, 2021, 158, 112-117.	0.6	15
188	Tissue factor expression in the metaplasia–adenoma–carcinoma sequence of gastric cancer in a European population. British Journal of Cancer, 2012, 107, 1125-1130.	6.4	14
189	Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity. Clinical and Translational Radiation Oncology, 2019, 18, 1-8.	1.7	14
190	The effect of hypoxia on PD-L1 expression in bladder cancer. BMC Cancer, 2021, 21, 1271.	2.6	14
191	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer and Prostatic Diseases, 2022, 25, 755-761.	3.9	14
192	A Potential Pitfall in the Use of Electroporation: Cellular Radiosensitization by Pulsed High-voltage Electric Fields. International Journal of Radiation Biology, 1992, 61, 329-334.	1.8	13
193	Pitfalls in Prediction Modeling for Normal Tissue Toxicity in Radiation Therapy: An Illustration With the Individual Radiation Sensitivity and Mammary Carcinoma Risk Factor Investigation Cohorts. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1466-1476.	0.8	13
194	Discussion. Radiotherapy and Oncology, 1999, 51, 109-111.	0.6	12
195	The radiobiology/radiation protection interface in healthcare. Journal of Radiological Protection, 2009, 29, A1-A20.	1.1	12
196	Improved accuracy and precision of tracer kinetic parameters by joint fitting to variable flip angle and dynamic contrast enhanced MRI data. Magnetic Resonance in Medicine, 2016, 76, 1270-1281.	3.0	12
197	Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas. Oncotarget, 2016, 7, 63106-63123.	1.8	12
198	A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis. British Journal of Cancer, 2022, 126, 1082-1090.	6.4	12

#	Article	IF	CITATIONS
199	Implications of Delayed Reproductive Cell Death (Lethal Mutations/Genomic Instability) for the Interpretation of Tissue Responses. International Journal of Radiation Biology, 1995, 68, 363-367.	1.8	11
200	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. Radiotherapy and Oncology, 2021, 159, 241-248.	0.6	11
201	Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[11C]-thymidine. Biochimica Et Biophysica Acta: Reviews on Cancer, 2004, 1705, 91-102.	7.4	10
202	Comparison of predicted and clinical response to radiotherapy: A radiobiology modelling study. Acta Oncológica, 2009, 48, 584-590.	1.8	10
203	FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas. BMC Research Notes, 2015, 8, 676.	1.4	10
204	Selection of endogenous control genes for normalising gene expression data derived from formalin-fixed paraffin-embedded tumour tissue. Scientific Reports, 2020, 10, 17258.	3.3	10
205	Developing Tumor Radiosensitivity Signatures Using LncRNAs. Radiation Research, 2021, 195, 324-333.	1.5	10
206	Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. Radiotherapy and Oncology, 2022, 168, 75-82.	0.6	10
207	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. Frontiers in Oncology, 2020, 10, 575909.	2.8	10
208	Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer. Journal of Clinical Oncology, 2022, 40, 2203-2212.	1.6	10
209	Additive interaction between tamoxifen and rifampicin in human biliary tract carcinoma cells. Cancer Letters, 1990, 55, 159-163.	7.2	9
210	Poor Prognosis Associated With Human Papillomavirus α7ÂGenotypes in Cervical Carcinoma Cannot Be ExplainedÂby Intrinsic Radiosensitivity. International Journal of Radiation Oncology Biology Physics, 2013, 85, e223-e229.	0.8	9
211	The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). British Journal of Cancer, 2017, 116, 649-657.	6.4	9
212	Cellular radiosensitivity in human severe-combined-immunodeficiency (SCID) syndromes. Radiotherapy and Oncology, 1997, 42, 53-57.	0.6	8
213	No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix. British Journal of Cancer, 2006, 94, 115-120.	6.4	8
214	Use of multiple biological markers in radiotherapy-treated head and neck cancer. Journal of Laryngology and Otology, 2010, 124, 650-658.	0.8	8
215	Immune infiltrate diversity confers a good prognosis in follicular lymphoma. Cancer Immunology, Immunotherapy, 2021, 70, 3573-3585.	4.2	8
216	Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy. PLoS ONE, 2018, 13, e0194841.	2.5	7

#	Article	IF	CITATIONS
217	A comparison of adriamycin and mAMSA. Cancer Chemotherapy and Pharmacology, 1987, 20, 109-14.	2.3	6
218	Prediction of radiotherapy response using SF2: Is it methodology or mythology?. Radiotherapy and Oncology, 1994, 31, 86-88.	0.6	6
219	Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation. Radiotherapy and Oncology, 2004, 70, 311-317.	0.6	6
220	Susuk charms? A case report. British Dental Journal, 2013, 215, 13-15.	0.6	6
221	Investigation of the epithelial to mesenchymal transition markers S100A4, vimentin and Snail1 in gastroesophageal junction tumors. Ecological Management and Restoration, 2014, 27, 485-492.	0.4	6
222	A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer. British Journal of Cancer, 2021, 125, 85-93.	6.4	6
223	Radiogenomic Predictors of Adverse Effects following Charged Particle Therapy. International Journal of Particle Therapy, 2018, 5, 103-113.	1.8	6
224	Development and Optimization of a Machine-Learning Prediction Model for Acute Desquamation After Breast Radiation Therapy in the Multicenter REQUITE Cohort. Advances in Radiation Oncology, 2022, 7, 100890.	1.2	6
225	Development and validation of a hypoxia-associated signature for lung adenocarcinoma. Scientific Reports, 2022, 12, 1290.	3.3	6
226	Effect of Race and Ethnicity on Risk of Radiotherapy Toxicity and Implications for Radiogenomics. Clinical Oncology, 2022, 34, 653-669.	1.4	6
227	A Human Colon Adenocarcinoma Xenograft—Radiation Response, Cellular Composition, and Tumor Disaggregation <xref ref-type="fn" rid="FN2">2</xref> . Journal of the National Cancer Institute, 1987, , .	6.3	5
228	Low-density Lipoprotein Uptake and the Sensitivity to Photodynamic Treatment of Cultured Endothelial Cells. International Journal of Radiation Biology, 1991, 60, 25-28.	1.8	5
229	The potential of PET to increase understanding of the biological basis of tumour and normal tissue response to radiotherapy. British Journal of Radiology, 2005, Supplement_28, 50-54.	2.2	5
230	Point: Why choose pulsed-dose-rate brachytherapy for treating gynecologic cancers?. Brachytherapy, 2009, 8, 269-272.	0.5	5
231	A Pilot Study to Investigate the Role of Thymidylate Synthase as a Marker of Prognosis for Neoadjuvant Chemotherapy in Gastric and Gastro-Oesophageal Junction Adenocarcinoma. Gastroenterology Research and Practice, 2013, 2013, 1-7.	1.5	5
232	Acute Epithelial Toxicity Is Prognostic for Improved Prostate Cancer Response to Radiation Therapy: A Retrospective, Multicenter, Cohort Study. International Journal of Radiation Oncology Biology Physics, 2018, 101, 957-963.	0.8	5
233	Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status. Journal of Cancer Research and Clinical Oncology, 2018, 144, 389-401.	2.5	5
234	Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer. BMC Urology, 2021, 21, 96.	1.4	5

#	Article	IF	CITATIONS
235	Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). Lung Cancer, 2022, 166, 228-241.	2.0	5
236	Comparison of Two Methods to Assess Tumour Vasculature in Human Cervical Carcinoma. International Journal of Radiation Biology, 1991, 60, 169-173.	1.8	4
237	Discrimination of human tumor radioresponsiveness using low-dose rate irradiation. International Journal of Radiation Oncology Biology Physics, 1998, 42, 1147-1153.	0.8	4
238	Exploiting sample variability to enhance multivariate analysis of microarray data. Bioinformatics, 2007, 23, 2733-2740.	4.1	4
239	Biomarkers and Imaging for Precision Radiotherapy. Clinical Oncology, 2015, 27, 545-546.	1.4	4
240	A new approach for modeling patient overall radiosensitivity and predicting multiple toxicity endpoints for breast cancer patients. Acta Oncológica, 2018, 57, 604-612.	1.8	4
241	Relationships between the Cytotoxic Effects of Restriction Endonucleases and Radiation on Mammalian Cells. International Journal of Radiation Biology, 1995, 67, 327-334.	1.8	3
242	Clinical Impact of Tumour Involvement of the Anastomotic Doughnut in Oesophagogastric Cancer Surgery. Annals of the Royal College of Surgeons of England, 2009, 91, 195-200.	0.6	3
243	The Case for Including Bowel Urgency in Toxicity Reporting After Pelvic Cancer Treatment. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 827-833.	4.9	3
244	Dynamics of circulating vascular endothelial growth factorâ€A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology, 2019, 85, 1781-1789.	2.4	3
245	Identifying the Radioresponsive Genome for Genomics-Guided Radiotherapy. Journal of the National Cancer Institute, 2021, 113, 223-224.	6.3	3
246	A data science approach for early-stage prediction of Patient's susceptibility to acute side effects of advanced radiotherapy. Computers in Biology and Medicine, 2021, 135, 104624.	7.0	3
247	Translational research in radiotherapy trials. British Journal of Radiology, 2006, 79, 716-718.	2.2	2
248	Radiobiologically derived biphasic fractionation schemes to overcome the effects of tumour hypoxia. British Journal of Radiology, 2020, 93, 20190250.	2.2	2
249	Bladder preservation: Translating discovery for clinical impact in urothelial cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 201-208.	1.6	2
250	Comparison of multiple gene expression platforms for measuring a bladder cancer hypoxia signature. Molecular Medicine Reports, 2022, 26, .	2.4	2
251	Genetic Predictors of Normal Tissue Response to Radiotherapy. , 2010, , 127-135.		1
252	Assessment of Drug Resistance in Anticancer Therapy by Nuclear Imaging. , 2009, , 295-313.		1

#	Article	IF	CITATIONS
253	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. Frontiers in Oncology, 2020, 10, 575909.	2.8	1
254	Late Radiation Morbidity in a Patient with Carcinoma of the Cervix. Clinical Oncology, 2002, 14, 437-441.	1.4	0
255	Erratum to "radiation response and cure of human colon adenocarcinoma spheroids of different size: the significance of hypoxia tumor control modelling― International Journal of Radiation Oncology Biology Physics, 2004, 58, 1322.	0.8	0
256	The REQUITE project: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side effects Journal of Clinical Oncology, 2014, 32, 276-276.	1.6	0
257	Hypoxia does not predict lack of benefit from adjuvant radiotherapy for patients with early stage breast cancer. British Journal of Cancer, 2022, , .	6.4	0
258	Positron emission tomography (PET) and anticancer drug development. Discovery Medicine, 2004, 4, 303-6.	0.5	0